ATE387201T1 - Pharmazeutische kombination von tenatoprazole und einem histamin-h2-rezeptor antagonisten - Google Patents

Pharmazeutische kombination von tenatoprazole und einem histamin-h2-rezeptor antagonisten

Info

Publication number: ATE387201T1
Authority: AT; Austria
Prior art keywords: tenatoprazole; histamine; receptor antagonist; pharmaceutical combination; magnesium
Prior art date: 2002-10-21

Application number

AT03778429T

Other languages

English (en)

Inventor

Francois Schutze

Suzy Charbit

Herve Ficheux

Michel Homerin

Alain Taccoen

Yoshio Inaba

Original Assignee

Sidem Pharma

Mitsubishi Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-21

Filing date

2003-10-21

Publication date

2008-03-15

2003-10-21 Application filed by Sidem Pharma, Mitsubishi Pharma Corp filed Critical Sidem Pharma

2008-03-15 Application granted granted Critical

2008-03-15 Publication of ATE387201T1 publication Critical patent/ATE387201T1/de

Links

ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 title abstract 2
229940122957 Histamine H2 receptor antagonist Drugs 0.000 title abstract 2
239000003485 histamine H2 receptor antagonist Substances 0.000 title abstract 2
229950008375 tenatoprazole Drugs 0.000 title abstract 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011591 potassium Substances 0.000 abstract 1
229910052700 potassium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03778429T 2002-10-21 2003-10-21 Pharmazeutische kombination von tenatoprazole und einem histamin-h2-rezeptor antagonisten ATE387201T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0213114A FR2845916B1 (fr)	2002-10-21	2002-10-21	Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine

Publications (1)

Publication Number	Publication Date
ATE387201T1 true ATE387201T1 (de)	2008-03-15

Family

ID=32050604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03778429T ATE387201T1 (de)	2002-10-21	2003-10-21	Pharmazeutische kombination von tenatoprazole und einem histamin-h2-rezeptor antagonisten

Country Status (18)

Country	Link
US (2)	US20060241136A1 (de)
EP (1)	EP1553944B1 (de)
JP (1)	JP5303093B2 (de)
KR (1)	KR101153571B1 (de)
CN (1)	CN1744896B (de)
AT (1)	ATE387201T1 (de)
AU (1)	AU2003285428A1 (de)
BR (1)	BR0315445A (de)
CA (1)	CA2503215C (de)
CY (1)	CY1107415T1 (de)
DE (1)	DE60319399T2 (de)
DK (1)	DK1553944T3 (de)
ES (1)	ES2299738T3 (de)
FR (1)	FR2845916B1 (de)
IL (1)	IL167590A (de)
PT (1)	PT1553944E (de)
SI (1)	SI1553944T1 (de)
WO (1)	WO2004037256A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2845915B1 (fr) *	2002-10-21	2006-06-23	Negma Gild	Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) *	2002-10-21	2006-07-07	Negma Gild	Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) *	2002-12-16	2006-07-28	Negma Gild	Enantiomere(-)du tenatoprazole et son application en therapeutique
FR2871800B1 (fr) *	2004-06-17	2006-08-25	Sidem Pharma Sa Sa	Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
WO2006043280A1 (en) *	2004-10-19	2006-04-27	Council Of Scientific And Industrial Research	Tenatoprazole salts and process of preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0643426B2 (ja) *	1986-07-25	1994-06-08	東京田辺製薬株式会社	イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
CA2180535C (en) *	1994-01-05	2004-03-23	Lindberg, Per Lennart	A method for treatment of psoriasis, by omeprazole or related compounds
US6362202B1 (en) *	1999-03-02	2002-03-26	Sepracor Inc.	Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
SE9903831D0 (sv) *	1999-10-22	1999-10-22	Astra Ab	Formulation of substituted benzimidazoles
US8206741B2 (en) *	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
FR2845915B1 (fr) *	2002-10-21	2006-06-23	Negma Gild	Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) *	2002-10-21	2006-07-07	Negma Gild	Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) *	2002-12-16	2006-07-28	Negma Gild	Enantiomere(-)du tenatoprazole et son application en therapeutique

2002
- 2002-10-21 FR FR0213114A patent/FR2845916B1/fr not_active Expired - Fee Related
2003
- 2003-10-21 CN CN2003801072007A patent/CN1744896B/zh not_active Expired - Fee Related
- 2003-10-21 KR KR1020057006843A patent/KR101153571B1/ko not_active Expired - Fee Related
- 2003-10-21 WO PCT/FR2003/003124 patent/WO2004037256A1/fr not_active Ceased
- 2003-10-21 DK DK03778429T patent/DK1553944T3/da active
- 2003-10-21 PT PT03778429T patent/PT1553944E/pt unknown
- 2003-10-21 CA CA2503215A patent/CA2503215C/fr not_active Expired - Fee Related
- 2003-10-21 SI SI200331135T patent/SI1553944T1/sl unknown
- 2003-10-21 AT AT03778429T patent/ATE387201T1/de active
- 2003-10-21 ES ES03778429T patent/ES2299738T3/es not_active Expired - Lifetime
- 2003-10-21 BR BR0315445-9A patent/BR0315445A/pt not_active IP Right Cessation
- 2003-10-21 AU AU2003285428A patent/AU2003285428A1/en not_active Abandoned
- 2003-10-21 DE DE60319399T patent/DE60319399T2/de not_active Expired - Lifetime
- 2003-10-21 EP EP03778429A patent/EP1553944B1/de not_active Expired - Lifetime
- 2003-10-21 US US10/532,114 patent/US20060241136A1/en not_active Abandoned
- 2003-10-21 JP JP2004546116A patent/JP5303093B2/ja not_active Expired - Fee Related
2005
- 2005-03-22 IL IL167590A patent/IL167590A/en not_active IP Right Cessation
2008
- 2008-04-21 CY CY20081100445T patent/CY1107415T1/el unknown
2011
- 2011-11-15 US US13/297,122 patent/US20120122919A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR101153571B1 (ko)	2012-06-11
AU2003285428A1 (en)	2004-05-13
US20060241136A1 (en)	2006-10-26
CN1744896A (zh)	2006-03-08
KR20050098831A (ko)	2005-10-12
CA2503215C (fr)	2012-02-21
IL167590A (en)	2009-05-04
DE60319399D1 (de)	2008-04-10
DE60319399T2 (de)	2009-02-19
CY1107415T1 (el)	2012-12-19
US20120122919A1 (en)	2012-05-17
SI1553944T1 (sl)	2008-12-31
ES2299738T3 (es)	2008-06-01
WO2004037256A1 (fr)	2004-05-06
FR2845916A1 (fr)	2004-04-23
FR2845916B1 (fr)	2006-07-07
JP5303093B2 (ja)	2013-10-02
DK1553944T3 (da)	2008-06-23
JP2006506377A (ja)	2006-02-23
CN1744896B (zh)	2011-08-31
EP1553944A1 (de)	2005-07-20
PT1553944E (pt)	2008-03-31
BR0315445A (pt)	2005-08-16
AU2003285428A8 (en)	2004-05-13
CA2503215A1 (fr)	2004-05-06
EP1553944B1 (de)	2008-02-27

Legal Events

Date

Code

Title

Description

2008-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1553944

Country of ref document: EP

Publication	Publication Date	Title
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ID26984A (id)	2001-02-22	Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
BR0110079A (pt)	2002-12-31	Combinação de compostos orgânicos
NO20052493D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
LU92595I2 (fr)	2015-11-02	Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
DK1501809T3 (da)	2008-05-13	Trizolderivater som tachykininreceptorantagonister
DE60322472D1 (de)	2008-09-11	Tiefeneinstellbare Knochenbohrlehre
NO20041504L (no)	2004-05-13	Lactamderivater som antagonister for humane 11CBY reseptorer.
EP1687686A4 (de)	2010-09-15	Hochparallele vermittlungssysteme mit fehlerkorrektur
DE60234616D1 (de)	2010-01-14	Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
DK1463759T3 (da)	2013-08-12	Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
ATE308522T1 (de)	2005-11-15	Opioidrezeptorantagonisten
NO20044373L (no)	2004-10-14	Azetidinderivater som CCR-3-reseptorantagonister
DK1636206T3 (da)	2008-02-11	Imidazolderivater som glutamatreceptorantagonister
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE419254T1 (de)	2009-01-15	5-ää(2,3-difluorophenyl)methylüthioü-7-ää2- hydroxy-1-(hydroxymethyl)-1-
CY1107415T1 (el)	2012-12-19	Φαρμακευτικη συνθεση η οποια συνδυαζει τενατοπροζολη και εναν ανταγωνιστη των υποδοχεων h2 της ισταμινης
DE60325613D1 (de)	2009-02-12	5-Ä((2,3-difluorophenyl)methyl)thioÜ-7-äÄ(1S,2S)-2-hydroxy-1-(hydroxymethyl)propylÜaminoüthiazoloÄ4,5-dÜpyrimidin-2(3H)-on als CXCR2 Antagonist
EA200601592A1 (ru)	2006-12-29	Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
IL178819A0 (en)	2007-03-08	Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
PL375263A1 (en)	2005-11-28	2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
ATE439354T1 (de)	2009-08-15	Pharmazeutische salze von reboxetin
ITRM20020434A0 (it)	2002-08-22	Procedimento per la sintesi di zolfo polimerico.
EA200501753A1 (ru)	2006-04-28	Антагонисты глутаматного рецептора в качестве нейрозащитных средств
EA200401617A1 (ru)	2005-06-30	Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера